HLDF-6

A synthetic hexapeptide (Thr-Gly-Glu-Asn-His-Arg) corresponding to residues 41–46 of human leukemia differentiation factor, studied almost entirely by one Russian research network — in rodent models of neurodegeneration and, on a separate track, as a tumor-cell differentiating agent — with no human trial anywhere.

Also referenced as: HLDF-6, HLDF6, TGENHR, HLDF-6 amide, HLDF-6-NH2, HLDF-6-OH, Thr-Gly-Glu-Asn-His-Arg

Also appears in: Cognitive

COAPublic product evidenceSearch the public certificate ledger for this compoundNo exact compound records are currently indexed under this profile name.→

---

What is HLDF-6?

HLDF-6 is a synthetic hexapeptide with the sequence Thr-Gly-Glu-Asn-His-Arg (TGENHR). It reproduces residues 41–46 of human leukemia differentiation factor (HLDF), a 54-amino-acid protein isolated from the culture medium of HL-60 promyelocytic leukemia cells treated with all-trans retinoic acid. Researchers at the Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry in Moscow narrowed the parent protein’s differentiation-inducing activity down to this six-residue stretch and found the isolated fragment retained it — the synthetic peptide reproduced the full-size factor’s ability to induce differentiation and arrest proliferation in the HL-60 cells it came from (Kostanyan et al., Russian Journal of Bioorganic Chemistry, 2000;26(7):505–511).

Its presence in the research-peptide market comes from a second line of work rather than the cancer-differentiation one it was named for: from the early 2000s onward the same network reported neuroprotective, memory-restoring, and anxiolytic effects in rodents, which is how a leukemia-differentiation fragment came to be discussed as a nootropic.

It is worth being blunt about scale. PubMed indexes 24 records under “HLDF-6” and 26 once spelling variants are counted — most in Russian-language journals, and effectively all of them from one Russian research network. The originating group itself claims more than thirty publications across twenty-plus years, which means a meaningful share of the work sits in journals PubMed does not index at all and cannot be checked by an outside reader. It is not stocked the way common research peptides are, and it has never been given to a human being in a registered study.

How it works

• Anti-apoptotic protection under chemical insult. HLDF-6 preserved rat hippocampal and cerebellar neurons against beta-amyloid toxicity in culture and reduced the number of pyknotic neurons in the hippocampal CA1 field in vivo (Kostanyan et al., Russian Journal of Bioorganic Chemistry, 2006;32(4):399–407). In the HL-60 cells where it was discovered, it blunted TNF-α cytotoxicity and reduced caspase-3 activation, which the authors attributed to interference with mitochondria-dependent apoptotic signaling rather than to NF-κB (Gibanova et al., Biochemistry (Moscow), 2007;72(1):49–60).
• Second-messenger effects with no identified receptor. The original characterization found no specific binding site for HLDF-6 on the surface of HL-60 cells, though the peptide did alter interleukin-1β binding to those cells (Kostanyan et al., 2000, above). A later comparison against its structural homolog reported that HLDF-6 lowers cyclic AMP by inhibiting adenylate cyclase, while the homolog inhibits phosphatidylinositol-specific phospholipase C — a different messenger system entirely (Zhokhov et al., Biochemistry (Moscow), 2004;69(8):861–869). More than two decades after the peptide was identified, no receptor for the peptide itself has been named in the published literature; the downstream targets that later papers invoke are neurotransmitter receptors, not binding sites for HLDF-6.
• Steroid-hormone modulation. In male NMRI mice, HLDF-6 raised testosterone roughly 1.5- to 2-fold in both intact and castrated animals and completely or partially restored castration-suppressed sexual activity and pain sensitivity; the authors proposed it both stimulates testosterone biosynthesis and inhibits its conversion to dihydrotestosterone by lowering 5α-reductase isoform 1 expression (Rzhevsky et al., Regulatory Peptides, 2005;127(1–3):111–121). In the amyloid model it suppressed a disease-associated rise in dihydrotestosterone (Kostanyan et al., 2006), and in the MPTP model it raised serum estradiol (Zolotarev et al., Neuropeptides, 2022;96:102287). The originating group treats this endocrine action as carrying a meaningful share of the neurological effect, which makes the compound’s mechanism as much systemic as neuronal.
• Neurotransmitter and neurotrophic shifts. Subchronic intranasal administration of the amide form increased NMDA receptor density in the hippocampus of stress-susceptible BALB/c mice while leaving GABA-A and nicotinic receptor density unchanged, and non-selectively lowered 5-HT2A density in the frontal cortex of both mouse strains tested (Zolotarev et al., Journal of Psychopharmacology, 2016;30(9):922–935). In MPTP-lesioned mice it restored striatal dopamine levels, increased BDNF messenger RNA, and normalized TGFβ1, IL-1β, and IFNγ transcripts (Zolotarev et al., 2022, above).

Research status

No human trials. ClinicalTrials.gov returns zero registered studies for HLDF-6, for HLDF, or for the sequence TGENHR. There is no FDA-approved product, no DailyMed label, and no approval in any jurisdiction. Everything below is animal, cell-culture, or ex vivo tissue work.

Alzheimer’s-model work is the deepest lane. Cognitive deficits induced in male rats by injecting beta-amyloid fragment 25–35 into the nucleus basalis of Meynert, or by co-injecting it with ibotenic acid into the hippocampus, were reported to improve with HLDF-6 across novel object recognition, passive avoidance, and Morris water maze testing; a head-to-head comparison found the C-terminal amide form outperformed the native free-acid peptide, which the authors credited to slower biodegradation and a longer half-life (Bogachouk et al., Journal of Psychopharmacology, 2016;30(1):78–92). An earlier study reported memory restoration after chronic intracerebroventricular Aβ(25–35) in rats, with HLDF-6 acting mainly on long-term memory while its PEDF homolog acted mainly on working memory (Storozheva et al., Bulletin of Experimental Biology and Medicine, 2006;141(3):319–322). The most developed report used B6C3-Tg(APPswe,PSEN1de9)85Dbo transgenic mice given 250 µg/kg intranasally and concluded the amide form restored disturbed cognitive function; that paper explicitly selected the amide form, the 250 µg/kg dose, and the intranasal route as the candidate for further development (Bogachouk et al., Acta Naturae, 2017;9(3):64–70).

Parkinson’s and ischemia models. In MPTP-lesioned C57Bl/6 mice, three weeks of intranasal HLDF-6 or its homoserine derivative HLDF-6H at 300 µg/kg/day restored striatal dopamine and improved performance on the horizontal grid test (Zolotarev et al., Neuropeptides, 2022;96:102287). A conference abstract on the homoserine derivative in Parkinson’s disease appeared in European Psychiatry (2025;68(S1):S840–S841) — a meeting abstract, not a peer-reviewed paper, and not a human study. Post-ischemic administration was reported to reduce cognitive dysfunction and brain damage after chronic cerebral ischemia in rats (Kostanyan et al., Doklady Biological Sciences, 2009;428:418–422).

Behavioral and other findings. The amide form showed anxiolytic activity in open field and elevated plus maze testing at 0.1 and 0.3 mg/kg intranasally, described as comparable to diazepam at 0.5 mg/kg, but the effect appeared only in stress-susceptible BALB/c mice and not in stress-resilient C57BL/6 mice (Zolotarev et al., 2016, above). Other scattered reports cover relief of naloxone-precipitated withdrawal signs in morphine-tolerant Wistar rats at 0.2 mg/kg (Litvinova et al., Bulletin of Experimental Biology and Medicine, 2004;137(5):447–449) and increased copulatory activity in 20- and 26-month-old male rats at 300 µg/kg daily for three weeks, without any change in circulating testosterone or estradiol — though that study used the homoserine amide (Thr-Gly-Glu-Hse-His-Arg-NH2), not the native sequence (Sokolov et al., Experimental Gerontology, 2021;149:111329). A pharmacokinetic study of the amide using tritium- and deuterium-labeled peptide in mice, rats, and rabbits calculated bioavailability at 34% and reported high resistance to hydrolysis in blood plasma, with dipeptidyl aminopeptidases the main route of breakdown (Zolotarev et al., Russian Journal of Bioorganic Chemistry, 2015;41(6):644–656).

Where the evidence is weak, and where it points the wrong way. The dose-response is not orderly: in the one study led from outside Russia, by a corresponding author at Cardiff University, HLDF6 improved water maze performance at 0.1 mg/kg but not at 1 mg/kg, while improving delayed matching-to-position at 0.3 and 1.0 mg/kg but not at 0.1 (Sewell et al., Journal of Psychopharmacology, 2005;19(6):602–608) — and that study was co-authored with the originating Moscow group, so it is a collaboration rather than an independent replication. A screen of peptides in mouse embryonic stem cells found HLDF-6 non-toxic but with an insignificant effect on differentiation into mature neurons (Kobylyanskii et al., Bulletin of Experimental Biology and Medicine, 2017;163(6):731–736). The parallel oncology lane runs in a different direction from the neuroprotection story: an N-acetyl amide form has been studied as an antitumor differentiating agent, most recently applied ex vivo to breast cancer biopsy material from 33 patients, where it increased differentiated-cell content only in the luminal B HER2-negative subtype and not in luminal A or basal-like tumors (Studenikina et al., Arkhiv Patologii, 2025;87(2):5–10) — while the same peptide’s anti-apoptotic action protected leukemia cells from TNF-α killing.

Development is parked. The Institute of Bioorganic Chemistry still lists the amide as a drug candidate — a dry lyophilisate for intranasal use, indicated for Alzheimer’s disease and ischemic stroke — but only at the active-pharmaceutical-substance stage, with Phase 1 presented as an investment opportunity still seeking funding. The core neuroprotection papers landed in 2016 and 2017. No registered clinical trial has followed.

Common dosage forms

• Lyophilized powder in vials for reconstitution, in the low-milligram range, is the format when the compound surfaces at all. It is not a routine catalog item and is more often obtained through custom peptide synthesis than bought off a shelf.
• Several distinct chemical forms circulate under nearly identical names: the native free acid (HLDF-6-OH, TGENHR), the C-terminal amide (HLDF-6-NH2, TGENHR-NH2 — the form most of the neurological work used), an N-acetyl/C-amide variant (HLDF-6-AA, Ac-TGENHR-NH2) studied in the antitumor lane, and a homoserine derivative designated HLDF-6H, which is not a formulation change at all but a different sequence, with homoserine replacing the asparagine at position 4 (Thr-Gly-Glu-Hse-His-Arg). Labeling frequently does not state which one is in the vial, and the published research treats them as behaving differently.
• The published animal work used intranasal solution and intraperitoneal injection. The intranasal route was the one explicitly selected for further development in the transgenic Alzheimer’s study.
• No oral, capsule, or topical presentation appears anywhere in the literature, and no pharmaceutical-grade product exists in any market.

This section describes formats only and is not dosing guidance.

Key considerations

• No one has ever been dosed with it, and the program appears to have stopped. Zero ClinicalTrials.gov records, no FDA or other regulatory approval, no DailyMed label. The only work touching human material is an ex vivo experiment on tumor biopsies — tissue in a dish, not a patient given a drug. The originating institute’s candidate sits at the active-substance stage with Phase 1 unfunded, and the main neuroprotection papers are now roughly a decade old. A gap that long after a completed preclinical package is itself information.
• The literature is a single network. Two dozen indexed papers, essentially all traceable to the Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry and a handful of collaborating Russian institutes — the Institute of Molecular Genetics and Kurchatov Institute in Moscow, plus a separate oncology cluster in Novosibirsk. The one paper led from a Western institution was co-authored with that same group. There is effectively no independent replication, and many of the reports are Russian-language with limited indexing, so the abstract is often all that is retrievable.
• The parent protein’s identity is itself unsettled. HLDF’s precursor shares an N-terminal sequence with ribosomal protein RPS21 and appears to arise from a different open reading frame of a near-identical messenger RNA, differing by two point deletions; the same authors reported finding neither a corresponding gene nor a pseudogene for HLDF anywhere in the human genome (Smirnova et al., Russian Journal of Bioorganic Chemistry, 2004;30(2):130–140). HLDF does not have the settled standing in mainstream human protein databases that the parent proteins of most named peptide fragments do. Numbering in this literature is loose in general — the group has published its PEDF homolog as residues 352–357 and, four years later, as 354–359 — though HLDF-6 itself is given consistently as 41–46.
• The mechanism is substantially endocrine, not purely neurological. Reported effects include a 1.5- to 2-fold testosterone increase in mice, suppression of dihydrotestosterone in one model, raised serum estradiol in another, and shifts in NMDA and 5-HT2A receptor density. Whatever else that is, it is systemic hormone-axis and CNS receptor activity in animals, in a compound with no human safety data of any kind.
• The name is a search trap. The bare acronym “HLDF” collides with unrelated technical uses — high-level data fusion in chemometrics and high-loaded dosage form in pharmaceutics — so automated literature searches on the acronym alone return mostly irrelevant papers. The hyphen matters too: “HLDF-6” and “HLDF6” return overlapping but non-identical PubMed sets, and the Cardiff study appears only under the unhyphenated form. HLDF-6 (TGENHR) is also easy to confuse with its close structural homolog PEDF-6 (TQVEHR), a fragment of pigment epithelium-derived factor that is frequently studied alongside it and reported to act through different signaling and to affect different aspects of memory.